Track topics on Twitter Track topics that are important to you
The purpose of this study is to record the number of patients with chronic renal disease who are receiving treatment with epoetin alfa or other recombinant erythropoietins who develop pure red cell aplasia (PRCA, a rare form of anemia) and/or antibodies to erythropoietin during the study period
Recombinant erythropoietins are effective in treating anemia caused by many diseases, including chronic renal disease. Pure red cell aplasia (PRCA, a rare form of anemia) and the development of antibodies to erythropoietin have been reported to occur infrequently in patients who are being treated with recombinant erythropoietin. The incidence of PRCA and antibody development is unknown. In this prospective, observational cohort study, specific information will be collected on patients with chronic renal disease who are receiving recombinant erythropoietin and their treatment course will be followed for up to 2 years. Patients will be treated by their individual physician for their chronic renal disease; no treatment or procedures will be specified and no medication will be given by the Sponsor of the study (Johnson and Johnson Pharmaceutical Research and Development, LLC). Upon entering the study, specific information will be collected regarding disease history and recombinant erythropoietin treatment. Every 3 months thereafter, progress information will be collected, including recombinant erythropoietin treatment, number of red blood cells and presence of any signs of PRCA development. If a confirmed or suspected diagnosis of PRCA is made, the date of diagnosis will also be recorded. Patients who develop PRCA will be offered the opportunity to enroll into another study specifically designed to follow PRCA patients for treatment, outcome and recovery. Additionally, blood samples will be collected at study entry and every 3 months for the purpose of screening/monitoring for antibodies to erythropoietin. If a patient's physician suspects PRCA or loss of effectiveness to erythropoietins at any other time during the study, an additional blood sample will be taken. Patients whose blood tests positive for antibodies to erythropoietin at any time will have blood sampled monthly until the tests are negative, at which time blood samples will be taken every 3 months until the completion of the study. Patients who discontinue erythropoietin will be followed only for an additional 12 months from the time erythropoietin is discontinued. All information will be collected in a confidential manner and identity of the patients will be protected. The results of this study will be combined with a similar study that does not collect blood samples to observe the number of patients who develop antibodies to erythropoietin. This study will initially enroll only patients with chronic renal disease who are being treated with a recombinant erythropoietin marketed by any of the Johnson and Johnson family of companies but may be expanded to enroll patients with other diseases and who have taken other recombinant erythropoietins. The study hypothesis is that the study will provide a framework for companion studies designed to investigate disease progression and population subgroup differences in further detail.
Since the study is purely an observation of patients who may develop PRCA, no treatment will be required by the Sponsor and no medication will be supplied by the Sponsor. Patients will receive standard-of-care treatment for their chronic renal (or other) disease from their individual physicians.
Observational Model: Defined Population, Primary Purpose: Screening, Time Perspective: Longitudinal, Time Perspective: Prospective
Red-Cell Aplasia, Pure
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Published on BioPortfolio: 2014-08-27T03:49:17-0400
The purpose of this study is to determine occurrence of pure red cell aplasia in a group of participants with chronic renal insufficiency and with resistance criteria to epoetin alfa treat...
The purpose of this study is to investigate a possible relationship between antibodies to recombinant erythropoietin and the clinical course of Pure Red Cell Anemia (PRCA) in patients curr...
The purpose of this study is to record the number of patients with chronic renal disease who are receiving treatment with epoetin alfa or other recombinant erythropoietins who develop pure...
Pure red cell aplasia (PRCA) is a kind of anemia characterized by severe reticulocytopenia and obvious bone marrow erythroblastic cells decreased. Cyclosporine and /or steroids are the fir...
A Study to Collect Information About Risk Factors in the Development of a Rare Form of Anemia (Pure Red Cell Aplasia; PRCA) and Antibodies to Erythropoietin From Patients With Kidney Disease Treated With Epoetin Alfa
The purpose of this study is to collect and compare information from patients with chronic kidney disease who were treated with a recombinant erythropoietin marketed by the Johnson and Joh...
Nivolumab is an antibody against programmed cell death 1 and functions as an immune checkpoint inhibitor for various malignancies, including unresectable melanomas. Nivolumab causes several immune-rel...
Aplasia cutis congenita (ACC), also called cutis aplasia, is a rare congenital abnormality characterized by focal defect of the skin at birth, frequently involving the scalp, but may affect any region...
Less than 5-7% of germ cell tumors (GCTs) are extragonadal, being the central nervous system (CNS) the most common location in children, followed by retroperitoneum and mediastinum. Only 10% of medias...
Mayer-Rokitansky-Kuster-Hauser (MRKH) syndrome is a congenital condition characterized by aplasia of the vagina with or without concurrent uterine and/or cervical aplasia. Type II (MURCS) is a rare fo...
To report on the use of endoscopic cyclophotocoagulation to treat congenital glaucoma in a triple X female with Microphthalmia, Dermal Aplasia, and Sclerocornea (MIDAS) syndrome.
Suppression of erythropoiesis with little or no abnormality of leukocyte or platelet production.
A syndrome of congenital facial paralysis, frequently associated with abducens palsy and other congenital abnormalities including lingual palsy, clubfeet, brachial disorders, cognitive deficits, and pectoral muscle defects. Pathologic findings are variable and include brain stem nuclear aplasia, facial nerve aplasia, and facial muscle aplasia, consistent with a multifactorial etiology. (Adams et al., Principles of Neurology, 6th ed, p1020)
Measurement of hearing based on the use of pure tones of various frequencies and intensities as auditory stimuli.
Gross hypo- or aplasia of one or more long bones of one or more limbs. The concept includes amelia, hemimelia, and phocomelia.
Cells artificially created by fusion of activated lymphocytes with neoplastic cells. The resulting hybrid cells are cloned and produce pure or "monoclonal" antibodies or T-cell products, identical to those produced by the immunologically competent parent, and continually grow and divide as the neoplastic parent.
Nephrology - kidney function
Nephrology is a specialty of medicine and pediatrics that concerns itself with the study of normal kidney function, kidney problems, the treatment of kidney problems and renal replacement therapy (dialysis and kidney transplantation). Systemic conditions...
Blood is a specialized bodily fluid that delivers necessary substances to the body's cells (in animals) – such as nutrients and oxygen – and transports waste products away from those same cells. In vertebrates, it is composed of blo...